EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Anthrax - Pipeline Review, H1 2017

  • ID: 4091113
  • Report
  • February 2017
  • 142 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Altimmune Inc
  • ContraFect Corp
  • GlaxoSmithKline Plc
  • iBio Inc
  • PaxVax Inc
  • Protein Potential LLC
  • MORE
Anthrax - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H1 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Anthrax - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 24 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Altimmune Inc
  • ContraFect Corp
  • GlaxoSmithKline Plc
  • iBio Inc
  • PaxVax Inc
  • Protein Potential LLC
  • MORE
Introduction

Anthrax - Overview

Anthrax - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anthrax - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anthrax - Companies Involved in Therapeutics Development

Altimmune Inc

Aphios Corp

Aradigm Corp

AtralCipan

ContraFect Corp

Crestone Inc

Dynavax Technologies Corp

Emergent BioSolutions Inc

GlaxoSmithKline Plc

Green Cross Corp

Grifols SA

Hawaii Biotech Inc

iBio Inc

Merck & Co Inc

Microbiotix Inc

NanoBio Corp

Paratek Pharmaceuticals Inc

PaxVax Inc

Pfenex Inc

PharmAthene Inc

Planet Biotechnology Inc

Protein Potential LLC

ProThera Biologics Inc

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

VLP Biotech Inc

Anthrax - Drug Profiles

anthrax (virus like particles) vaccine - Drug Profile

anthrax + plague vaccine - Drug Profile

anthrax vaccine - Drug Profile

anthrax vaccine - Drug Profile

anthrax vaccine - Drug Profile

anthrax vaccine - Drug Profile

anthrax vaccine - Drug Profile

anthrax vaccine - Drug Profile

Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile

ARD-3100 - Drug Profile

AV-7909 - Drug Profile

BDM-I - Drug Profile

CF-306 - Drug Profile

CF-307 - Drug Profile

CF-308 - Drug Profile

ciprofloxacin hydrochloride - Drug Profile

CPN-1311 - Drug Profile

DPX-Anthrax - Drug Profile

DV-230 - Drug Profile

Epimerox - Drug Profile

EV-035 - Drug Profile

GC-1109 - Drug Profile

gepotidacin mesylate - Drug Profile

GREANX - Drug Profile

KKL-35 - Drug Profile

Marinus - Drug Profile

Monoclonal Antibody for Anthrax - Drug Profile

Monoclonal Antibody for Anthrax - Drug Profile

Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile

Nasoshield - Drug Profile

omadacycline tosylate - Drug Profile

PBI-220 - Drug Profile

Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile

Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile

Px-563L - Drug Profile

Px-563L Second Generation - Drug Profile

raxibacumab - Drug Profile

RiVax + SGX-204 - Drug Profile

rPA-01 - Drug Profile

RPA-563 - Drug Profile

Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile

Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile

Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile

Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile

Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile

Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile

Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile

solithromycin - Drug Profile

TP-271 - Drug Profile

Anthrax - Dormant Projects

Anthrax - Discontinued Products

Anthrax - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Anthrax, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Anthrax - Pipeline by Altimmune Inc, H1

Anthrax - Pipeline by Aphios Corp, H1

Anthrax - Pipeline by Aradigm Corp, H1

Anthrax - Pipeline by AtralCipan, H1

Anthrax - Pipeline by ContraFect Corp, H1

Anthrax - Pipeline by Crestone Inc, H1

Anthrax - Pipeline by Dynavax Technologies Corp, H1

Anthrax - Pipeline by Emergent BioSolutions Inc, H1

Anthrax - Pipeline by GlaxoSmithKline Plc, H1

Anthrax - Pipeline by Green Cross Corp, H1

Anthrax - Pipeline by Grifols SA, H1

Anthrax - Pipeline by Hawaii Biotech Inc, H1

Anthrax - Pipeline by iBio Inc, H1

Anthrax - Pipeline by Merck & Co Inc, H1

Anthrax - Pipeline by Microbiotix Inc, H1

Anthrax - Pipeline by NanoBio Corp, H1

Anthrax - Pipeline by Paratek Pharmaceuticals Inc, H1

Anthrax - Pipeline by PaxVax Inc, H1

Anthrax - Pipeline by Pfenex Inc, H1

Anthrax - Pipeline by PharmAthene Inc, H1

Anthrax - Pipeline by Planet Biotechnology Inc, H1

Anthrax - Pipeline by Protein Potential LLC, H1

Anthrax - Pipeline by ProThera Biologics Inc, H1

Anthrax - Pipeline by Soligenix Inc, H1

Anthrax - Pipeline by Syntiron LLC, H1

Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H1

Anthrax - Pipeline by VLP Biotech Inc, H1

Anthrax - Dormant Projects, H1

Anthrax - Dormant Projects, H1 2017 (Contd..1), H1

Anthrax - Dormant Projects, H1 2017 (Contd..2), H1

Anthrax - Discontinued Products, H1

List of Figures:

Number of Products under Development for Anthrax, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Altimmune Inc
  • Aphios Corp
  • Aradigm Corp
  • AtralCipan
  • ContraFect Corp
  • Crestone Inc
  • Dynavax Technologies Corp
  • Emergent BioSolutions Inc
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Grifols SA
  • Hawaii Biotech Inc
  • iBio Inc
  • Merck & Co Inc
  • Microbiotix Inc
  • NanoBio Corp
  • Paratek Pharmaceuticals Inc
  • PaxVax Inc
  • Pfenex Inc
  • PharmAthene Inc
  • Planet Biotechnology Inc
  • Protein Potential LLC
  • ProThera Biologics Inc
  • Soligenix Inc
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
  • VLP Biotech Inc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll